Assyro AI

Orange Book product · Generic (ANDA)

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Generic (ANDA)ANDA 214287TE AARX QUAGEN

At a glance

Jan 18, 2024

Approved

Generic (ANDA)

Application

AA

TE code

None

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jan 18, 2024

    2 yr 5 mo ago

  2. Today

Pharmaceutical detail

Active ingredient

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Strength

325MG;50MG;40MG

Dosage form

TABLET

Route

ORAL

TE code

AA

Application

ANDA 214287

Product number

001

Marketing status

RX

Reference listed drug (RLD)

No

Reference standard (RS)

No

Active-ingredient family

View full family

Generic (ANDA) of ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.